In Season 3 of Invent: Life Sciences, we explored the forces redefining how tomorrow’s therapies will be developed, made, and delivered. From the challenges of scaling cell and gene therapy manufacturing to the transformative power of sustainability and AI, this season uncovered what it truly takes to move from discovery to delivery.Featuring insights from leaders across Novartis, Cellular Origins, Orchard Therapeutics, Charles River, Cytiva, OmniaBio, Eli Lilly, and more, this season revealed how the biotech industry must evolve to make breakthrough therapies accessible, affordable, and ready for global deployment.
--------
2:29
--------
2:29
Make Way for Advanced Therapies – Why Manufacturing Could be Coming to a Hospital Near You
In our last episode, we explored the manufacturing strategies that will be key to scaling advanced therapies. Now, we turn our focus to the UK, where new regulatory frameworks and regional collaboration are changing how therapies reach patients.Stuart speaks with leading experts about the evolution of regulation, the role of the MHRA, and why decentralized manufacturing could unlock faster, more flexible access to treatments. He also hears how Cambridge is preparing to become a regional hub for manufacturing, and what this shift could mean for patients across the East of England and beyond. Together, these perspectives reveal how regulation, clinical insight, and patient needs are converging to shape the next chapter of cell and gene therapy in the UK.Guests:Jacqueline Barry, Chief Clinical Officer, Cell and Gene Therapy CatapultSarah Albon, Director, Cambridge Cellular Therapy Laboratory at Cambridge University Hospitals NHS Foundation Trust
--------
38:05
--------
38:05
Automation, Access, and the Future of Manufacturing
Manufacturing can make or break the future of cell and gene therapy. In this episode, Stuart sits down with two expert guests to share how smart design, automation, and closed systems are helping to lower costs, reduce complexity, and make therapies more accessible. From scaling strategies to operator-friendly technology, they reveal why manufacturing isn’t just a back-end process, but a critical part of therapy development from day one.Guests:Professor Mark Lowdell, CSO InMune Bio IncLuc Henry, Founder and CEO at Limula
--------
37:25
--------
37:25
Scaling Cell & Gene Therapies: From Breakthroughs to the Mass Market
In this two-part series, host Stuart Lowe examines the barriers and breakthroughs that will determine whether cell and gene therapies can scale. From smarter manufacturing to new policy frameworks, join leading experts as they discuss what must change for CGTs to deliver on their full potential.
--------
3:32
--------
3:32
From Promise to Practice – AI's Impact on Cell and Gene Therapy Development
In this episode, Stuart explores the adoption of generative AI in the pharmaceutical industry, with a special focus on cell and gene therapy. While the application of AI for drug discovery has been well documented and a source of considerable investment for the pharmaceutical sector, we are only just starting to see its impact for therapy developers. A 2024 report from McKinsey Global Institute estimates that generative AI could generate up to $100 billion in economic value for pharma and medical product companies, and therapy developers are eager to see these benefits sooner rather than later, no more so than in the complex and challenging field of cell and gene therapies. With the help of two expert guests, Stuart will uncover how AI is being used in the industry today, and where it could go in the future. Guests:Ken Harris, Chief Strategy Officer and Head of AI at OmniaBioSean Bedingfield, PhD, Senior Advisor at Eli Lilly Genetic Medicine
What are the biggest challenges and opportunities facing the life sciences sector? How can we overcome these challenges while unlocking the opportunities? Join host Stuart Lowe and a roster of expert guests as they unpack the past, present and future of cell and gene therapy.
Ireland